{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=78", "query": { "condition": "Immunity Disorders", "page": 78 }, "page_size": 10 }, "pagination": { "page": 78, "page_size": 10, "total_count": 21216, "total_pages": 2122, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=79&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Immunity+Disorders&page=77&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T20:21:46.789Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03489525", "title": "MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Multiple Myeloma" ], "interventions": [ { "name": "Dose Escalation, MEDI2228, ADC (antibody drug conjugate)", "type": "BIOLOGICAL" }, { "name": "Dose Expansion, MEDI2228, ADC (antibody drug conjugate)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 107, "start_date": "2018-05-08", "completion_date": "2022-03-21", "has_results": false, "last_update_posted_date": "2022-03-28", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03489525" }, { "nct_id": "NCT06467084", "title": "Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "KVD900 150 mg", "type": "DRUG" }, { "name": "KVD900 300 mg", "type": "DRUG" }, { "name": "KVD900 600 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "KalVista Pharmaceuticals, Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "2 Years to 11 Years" }, "enrollment_count": 36, "start_date": "2024-08-01", "completion_date": "2026-01-15", "has_results": true, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06467084" }, { "nct_id": "NCT00038558", "title": "Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin Disease" ], "interventions": [ { "name": "Filgrastim SD/01", "type": "DRUG" }, { "name": "Adriamycin", "type": "DRUG" }, { "name": "Bleomycin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "DTIC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 25, "start_date": "2001-11", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00038558" }, { "nct_id": "NCT01478048", "title": "Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "BIOLOGICAL" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2011-11-30", "completion_date": "2017-04-21", "has_results": true, "last_update_posted_date": "2018-05-21", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 42, "location_summary": "Corona, California • Long Beach, California • Los Angeles, California + 35 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01478048" }, { "nct_id": "NCT04058743", "title": "Nickel Sensitivity", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Knee Arthropathy", "Allergic Reaction" ], "interventions": [ { "name": "TKA with nickel free components", "type": "DEVICE" }, { "name": "TKA with standard cobalt chromium components", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2019-09-27", "completion_date": "2024-12-21", "has_results": true, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04058743" }, { "nct_id": "NCT00880815", "title": "Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD20 Positive", "Chronic Lymphocytic Leukemia", "Follicular Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "T-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 60, "start_date": "2009-02-17", "completion_date": "2019-05-28", "has_results": false, "last_update_posted_date": "2019-06-03", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00880815" }, { "nct_id": "NCT00763035", "title": "Comparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Coronary Artery Disease", "Asthma", "Chronic Obstructive Pulmonary Disease (COPD)", "Angina" ], "interventions": [ { "name": "Regadenoson", "type": "DRUG" }, { "name": "Dobutamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2009-01", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00763035" }, { "nct_id": "NCT04665115", "title": "Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asymptomatic COVID-19 Infection Laboratory-Confirmed", "B-Cell Neoplasm", "Chronic Lymphocytic Leukemia", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "Small Lymphocytic Lymphoma", "Symptomatic COVID-19 Infection Laboratory-Confirmed", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-11-23", "completion_date": "2022-07-22", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665115" }, { "nct_id": "NCT03228004", "title": "Type 1 Diabetes Data Acquisition and Transfer Adherence Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Glooko MeterSync", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 53, "start_date": "2017-07-26", "completion_date": "2019-04-08", "has_results": false, "last_update_posted_date": "2019-04-12", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228004" }, { "nct_id": "NCT00114738", "title": "EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle Cell", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Rituximab (R)", "type": "DRUG" }, { "name": "EPOCH", "type": "BIOLOGICAL" }, { "name": "Bortezomib (B)", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Bortezomib or observation", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 53, "start_date": "2005-06-15", "completion_date": "2022-08-11", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-11-01T20:21:46.789Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00114738" } ] }